Description

Book Synopsis

The definitive book on the neutralization of recombinant biopharmaceuticals

Recombinant biopharmaceuticals are an important tool for treating a range of illnesses; however, their efficacy can be severely impaired by their immunogenicity. When introduced into the body, these pharmaceuticals can cause the immune system to produce anti-drug antibodies (ADAs) that neutralize their effects.

The first and only book to cover neutralization in connection with biopharmaceuticals and the measurement and application of neutralizing antibodies in modern medicine at any real length, Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations offers a comprehensive and in-depth look at all the principal aspects of the detection and quantification of antibodies that are essential to understanding and responding to the challenges they present.

Bringing together a large-scale review of neutralization and biopharmaceuticals and the abili

Table of Contents
INTRODUCTION: A PERSPECTIVE ix
Michael G. Tovey

CONTRIBUTORS xxi

PART I RISK-BASED STRATEGIES 1

1 Principles of Risk Assessment and Monitoring of Antibody Responses to Biopharmaceuticals 3
Eugen Koren, Erik Foehr, and Charles A. O’Neill

PART II REGULATORY REQUIREMENTS 13

2 Immunogenicity of Therapeutic Proteins: A Regulatory Perspective 15
Susan Kirshner

3 Guidance on Immunogenicity Assessment of Biologically Derived Therapeutic Proteins: A European Perspective 37
Meenu Wadhwa and Robin Thorpe

4 Japanese Regulatory Perspective on Immunogenicity 57
Takao Hayakawa and Akiko Ishii-Watabe

PART III PRINCIPAL TECHNOLOGIES EMPLOYED FOR THE QUANTIFICATION OF ANTI-DRUG ANTIBODIES 81

5 Enzyme Immunoassays and Radioimmunoassays for Quantification of Anti-TNF Biopharmaceuticals and Anti-Drug Antibodies 83
Klaus Bendtzen and Morten Svenson

6 Confirmatory Immunogenicity Assays 103
Eric Wakshull and Daniel Coleman

7 The Use of Pharmacodynamics as a Surrogate Marker for the Detection of Anti-Drug Neutralizing Antibodies 119
Florian Deisenhammer

8 Cell-Based Assays for the Detection of Neutralizing Antibodies to Interferon Beta (IFN-β) and Tumor Necrosis Factor Alpha (TNF-α) Inhibitors 133
Anthony Meager

9 Detection of Neutralizing Antibodies against Interferon Beta by Real-Time RT-PCR 157
Francesca Gilli and Antonio Bertolotto

10 Competitive Ligand-Binding Assays for the Detection of Neutralizing Antibodies 175
Bonnie W. Wu, George R. Gunn III, and Gopi Shankar

11 The Use of Surface Plasmon Resonance for the Detection and Characterization of Antibodies 193
Steven J. Swanson and Daniel Mytych

12 Hypersensitivity Reactions to Biopharmaceuticals: Detection and Quantification of Drug-Specific IgE Antibodies 211
Jörgen Dahlström and Lennart Venemalm

PART IV ASSAY STANDARDIZATION AND VALIDATION 233

13 Standardization and Validation of Immunoassays 235
Daniel Kramer

14 Standardization and Validation of Cell-Based Assays for the Detection of Neutralizing Anti-Drug Antibodies 243
Deborah Finco-Kent and Amy Grenham

15 Standardization of Neutralizing Antibody Unitage by Bioassay Design: Constant Antigen and Constant Antibody Methodology 269
Sidney E. Grossberg, Yoshimi Kawade, and Leslie D. Grossberg

PART V STATISTICAL CONSIDERATIONS 287

16 Cut Points and Performance Characteristics for Anti-Drug Antibody Assays 289
Viswanath Devanarayan and Michael G. Tovey

17 Dilutional Linearity for Neutralizing Antibody Assays 309
David Lansky and Carrie Wager

PART VI ADAPTATION OF ANTI-DRUG ANTIBODY ASSAYS TO CHALLENGING CONDITIONS 319

18 Detection of Antibodies to Biopharmaceuticals in the Presence of High Levels of Circulating Drug 321
Arno Kromminga and Michael G. Tovey

19 Antibody Assays in Animal Research 331
Vera Brinks, Francesca Gilli, Melody Sauerborn, and Huub Schellekens

20 Immunogenicity of Microbial Digestive Enzymes for Oral Replacement Therapy in Pancreatic Exocrine Insufficiency 343
Claudia Berger and Uwe Niesner

PART VII NOVEL TECHNOLOGIES FOR THE QUANTIFICATION OF NEUTRALIZING ANTIBODIES 369

21 Measurement of Biologically Active Drug as an Approach to Detection of Anti-Drug Neutralizing Antibodies 371
Yao Zhuang and Shalini Gupta

22 A Novel One-Step Cell-Based Assay for Quantification of Neutralizing Antibodies to Biopharmaceuticals 383
Christophe Lallemand and Michael G. Tovey

INDEX 399

Detection and Quantification of Antibodies to

    Product form

    £121.46

    Includes FREE delivery

    RRP £134.95 – you save £13.49 (9%)

    Order before 4pm today for delivery by Sat 4 Jul 2026.

    A Hardback by Michael G. Tovey

      Trusted by thousands of customers. See 2,385+ Customer Reviews

      View other formats and editions of Detection and Quantification of Antibodies to by Michael G. Tovey

      Publisher: John Wiley & Sons Inc
      Publication Date: 02/09/2011
      ISBN13: 9780470566664, 978-0470566664
      ISBN10: 0470566663

      Description

      Book Synopsis

      The definitive book on the neutralization of recombinant biopharmaceuticals

      Recombinant biopharmaceuticals are an important tool for treating a range of illnesses; however, their efficacy can be severely impaired by their immunogenicity. When introduced into the body, these pharmaceuticals can cause the immune system to produce anti-drug antibodies (ADAs) that neutralize their effects.

      The first and only book to cover neutralization in connection with biopharmaceuticals and the measurement and application of neutralizing antibodies in modern medicine at any real length, Detection and Quantification of Antibodies to Biopharmaceuticals: Practical and Applied Considerations offers a comprehensive and in-depth look at all the principal aspects of the detection and quantification of antibodies that are essential to understanding and responding to the challenges they present.

      Bringing together a large-scale review of neutralization and biopharmaceuticals and the abili

      Table of Contents
      INTRODUCTION: A PERSPECTIVE ix
      Michael G. Tovey

      CONTRIBUTORS xxi

      PART I RISK-BASED STRATEGIES 1

      1 Principles of Risk Assessment and Monitoring of Antibody Responses to Biopharmaceuticals 3
      Eugen Koren, Erik Foehr, and Charles A. O’Neill

      PART II REGULATORY REQUIREMENTS 13

      2 Immunogenicity of Therapeutic Proteins: A Regulatory Perspective 15
      Susan Kirshner

      3 Guidance on Immunogenicity Assessment of Biologically Derived Therapeutic Proteins: A European Perspective 37
      Meenu Wadhwa and Robin Thorpe

      4 Japanese Regulatory Perspective on Immunogenicity 57
      Takao Hayakawa and Akiko Ishii-Watabe

      PART III PRINCIPAL TECHNOLOGIES EMPLOYED FOR THE QUANTIFICATION OF ANTI-DRUG ANTIBODIES 81

      5 Enzyme Immunoassays and Radioimmunoassays for Quantification of Anti-TNF Biopharmaceuticals and Anti-Drug Antibodies 83
      Klaus Bendtzen and Morten Svenson

      6 Confirmatory Immunogenicity Assays 103
      Eric Wakshull and Daniel Coleman

      7 The Use of Pharmacodynamics as a Surrogate Marker for the Detection of Anti-Drug Neutralizing Antibodies 119
      Florian Deisenhammer

      8 Cell-Based Assays for the Detection of Neutralizing Antibodies to Interferon Beta (IFN-β) and Tumor Necrosis Factor Alpha (TNF-α) Inhibitors 133
      Anthony Meager

      9 Detection of Neutralizing Antibodies against Interferon Beta by Real-Time RT-PCR 157
      Francesca Gilli and Antonio Bertolotto

      10 Competitive Ligand-Binding Assays for the Detection of Neutralizing Antibodies 175
      Bonnie W. Wu, George R. Gunn III, and Gopi Shankar

      11 The Use of Surface Plasmon Resonance for the Detection and Characterization of Antibodies 193
      Steven J. Swanson and Daniel Mytych

      12 Hypersensitivity Reactions to Biopharmaceuticals: Detection and Quantification of Drug-Specific IgE Antibodies 211
      Jörgen Dahlström and Lennart Venemalm

      PART IV ASSAY STANDARDIZATION AND VALIDATION 233

      13 Standardization and Validation of Immunoassays 235
      Daniel Kramer

      14 Standardization and Validation of Cell-Based Assays for the Detection of Neutralizing Anti-Drug Antibodies 243
      Deborah Finco-Kent and Amy Grenham

      15 Standardization of Neutralizing Antibody Unitage by Bioassay Design: Constant Antigen and Constant Antibody Methodology 269
      Sidney E. Grossberg, Yoshimi Kawade, and Leslie D. Grossberg

      PART V STATISTICAL CONSIDERATIONS 287

      16 Cut Points and Performance Characteristics for Anti-Drug Antibody Assays 289
      Viswanath Devanarayan and Michael G. Tovey

      17 Dilutional Linearity for Neutralizing Antibody Assays 309
      David Lansky and Carrie Wager

      PART VI ADAPTATION OF ANTI-DRUG ANTIBODY ASSAYS TO CHALLENGING CONDITIONS 319

      18 Detection of Antibodies to Biopharmaceuticals in the Presence of High Levels of Circulating Drug 321
      Arno Kromminga and Michael G. Tovey

      19 Antibody Assays in Animal Research 331
      Vera Brinks, Francesca Gilli, Melody Sauerborn, and Huub Schellekens

      20 Immunogenicity of Microbial Digestive Enzymes for Oral Replacement Therapy in Pancreatic Exocrine Insufficiency 343
      Claudia Berger and Uwe Niesner

      PART VII NOVEL TECHNOLOGIES FOR THE QUANTIFICATION OF NEUTRALIZING ANTIBODIES 369

      21 Measurement of Biologically Active Drug as an Approach to Detection of Anti-Drug Neutralizing Antibodies 371
      Yao Zhuang and Shalini Gupta

      22 A Novel One-Step Cell-Based Assay for Quantification of Neutralizing Antibodies to Biopharmaceuticals 383
      Christophe Lallemand and Michael G. Tovey

      INDEX 399

      Recently viewed products

      © 2026 Book Curl

        • American Express
        • Apple Pay
        • Diners Club
        • Discover
        • Google Pay
        • Maestro
        • Mastercard
        • PayPal
        • Shop Pay
        • Union Pay
        • Visa

        Login

        Forgot your password?

        Don't have an account yet?
        Create account